Home
About +
Our Science +
Investors +
Contact

Home
About
Our Science
Investors
Contact

Our Story
Meet the Team
FAQs

Inhaled IFN-β
Clinical Trials
Publications
Factsheets

Members Voluntary Liquidation (MVL)
Investor Overview
Investor News
Reports & Presentations
Major Shareholders & Advisers
Shareholder Information
TR-1/Options Press Release Archive

Synairgen Safety Data with SNG001 in COPD Patients

Our Science
Interferon Beta
The INVENT global phase 2 clinical study
Investigating antiviral treatment in COVID-19
Prior studies investigating antiviral treatment in COPD
Prior studies investigating antiviral treatment in asthma
Relevant Publications
Factsheets

About
Home
Our Story
Team
FAQs
Contact

Investors
Members Voluntary Liquidation (MVL)
Investors Overview
Investor News
Reports & Presentations
Asset Match
Subscribe to news

Cookie Policy Legal Privacy Policy change

© Synairgen. All Rights ReservedRegistered in England and Wales No. 5233429 | Site by Ether